Clinical Efficacy of Benazepril in Dogs with Chronic Degenerative Valvular Diseases

• Main Authors: Shih-Yang Wu, 伍世揚
• Other Authors: Hui-Pi Huang
• Format: Others
• Language: en_US
• Published: 2008
• Online Access: http://ndltd.ncl.edu.tw/handle/74098275991302507777

碩士 === 國立臺灣大學 === 獸醫學研究所 === 97 === Abstract Benazepril, an angiotensin converting enzyme inhibitor, potently suppresses renin-angiotensin-aldosterone system, and is widely used in humans and dogs with hypertension, cardiac diseases, and renal diseases. In clinical studies, benazepril has been proven to have beneficial effect on hemodynamic parameters, clinical conditions, exercise endurance and survival times in dogs with congestive heart failure. Moreover, effect of benazepril on slowing down the progression of renal disease in patients with chronic renal insufficiency has been demonstrated. This thesis includes 3 studies, examinating clinical efficacy of benazpril on systemic blood pressure, conventional echocardiographic indices, speckle tracking echocardiographic variables and radiographic heart scale in small breed dogs with mild to severe heart failure caused by chronic degenerative valvular disease. Result of the first parf of study showed that benazepril improved clinical condition but did not change systemic blood pressure. Result of the second part of study indicated that benazepril had significant effect on improving left atrial indices, end-systolic ventricular indices, and ventricular contractility assessing using M-mode echocardiography, and on reducing radiographic heart scale. Result of the third part of study revealed that benazepril did not have beneficial effect on improving left ventricular segmental myocardial systolic and diastolic function.